Illya Aronskyy

BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…

BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…

INTRODUCTION: Point-of-care intestinal ultrasound (IUS) is a non-invasive, accurate inflammatory bowel disease (IBD) monitoring tool. As IUS uptake grows and monitoring strategies become more complex, understanding the impact of IUS on clinical decision-making and monitoring preferences is needed…

INTRODUCTION: Stride-II recommends early biomarker targets for treatment optimization to achieve treat-to-target (T2T) endoscopic remission (ER) in ulcerative colitis (UC). Predictive capabilities of intestinal ultrasound (IUS) for T2T ER remains unknown…